Stock Events

Stock Events

Epigenomics 

0
12
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-1,850%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
28,000Revenue
-518,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ECX0.MU. It's not an investment recommendation.
NVIDIA
2
NVDA
CD Projekt Red SA
2
7CD.F
Agenus
2
AGEN
Imperial Petroleum
2
IMPP

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health provides liquid biopsy tests for cancer detection, competing in the non-invasive cancer diagnostics market.
Illumina
ILMN
Mkt Cap32.55B
Illumina offers genomic sequencing technologies and services, enabling cancer detection and research that competes with Epigenomics' products.
Qiagen NV
QGEN
Mkt Cap8.9B
Qiagen provides sample and assay technologies for molecular diagnostics, including cancer, competing in the same space as Epigenomics.
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics offers genetic testing to detect cancer, among other conditions, competing with Epigenomics' diagnostic tests.
Myriad Genetics
MYGN
Mkt Cap302.25M
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers sequencing systems that could be used in cancer research and diagnostics, indirectly competing with Epigenomics' diagnostic technologies.

About

Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The company was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo G. Gut in 1998 and is headquartered in Berlin, Germany.
Show more...
CEO
Jason Wouhra
Employees
3
Country
Germany
ISIN
US29428N2018
WKN
000A3D30W

Listings

MU
DE
ECX0.MU
STU
DE
ECX.STU
MU
DE
ECX.MU
LSE
GB
0QXH.LSE

0 Comments

Share your thoughts

FAQ

What is Epigenomics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Epigenomics stocks are traded under the ticker ECX0.MU.
What is Epigenomics revenue for the last year?▼
Epigenomics revenue for the last year amounts to 28,000 EUR.
What is Epigenomics net income for the last year?▼
ECX0.MU net income for the last year is -518,000 EUR.
How many employees does Epigenomics have?▼
As of September 05, 2026, the company has 3 employees.
In which sector is Epigenomics located?▼
Epigenomics operates in the Health & Wellness sector.
When did Epigenomics complete a stock split?▼
Epigenomics has not had any recent stock splits.
Where is Epigenomics headquartered?▼
Epigenomics is headquartered in Heidelberg, Germany.